Payment overview · 2025
General Payments
$453.66
18 reported records · 10 companies
Healthcare provider profile · identity verified
Timothy Robert Quiner, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CORVALLIS, OR · NPI 1912989575
Verified facts
What the public records show
CMS Open Payments records show Timothy Robert Quiner, M.D. received $453.66 in general payments during 2025 across 18 reported records.
SANOFI PASTEUR INC. accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $114.32 | 25.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $63.06 | 13.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.36 | 13.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.84 | 11.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.22 | 11.1% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $32.94 | 7.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.26 | 5.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.06 | 4.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.05 | 4.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.55 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $437.67 | 17 |
| Education | $15.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $114.32 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.44 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.99 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.36 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $33.24 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $32.94 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.82 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $24.26 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.95 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $19.92 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 47 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 244 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 227 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 205 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 179 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 155 | 42 |
| Losartan Potassium | Losartan Potassium | 153 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 145 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 39 |
| Simvastatin | Simvastatin | 127 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 38 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 28 |
| Omeprazole | Omeprazole | 98 | 23 |
| Gabapentin | Gabapentin | 96 | 29 |
| Metformin Hcl | Metformin Hcl | 94 | 28 |
| Lovastatin | Lovastatin | 81 | 20 |
| Tramadol Hcl | Tramadol Hcl | 81 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 13 |
| Trazodone Hcl | Trazodone Hcl | 65 | 16 |
| Chlorthalidone | Chlorthalidone | 62 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 27 |
| Atenolol | Atenolol | 53 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 17 |
| Meloxicam | Meloxicam | 49 | 19 |
| Eliquis | Apixaban | 47 | 13 |
| Glipizide Er | Glipizide | 47 | 13 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Alprazolam | Alprazolam | 44 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 44 | 16 |
| Potassium Chloride | Potassium Chloride | 42 | 15 |
| Memantine Hcl Er | Memantine Hcl | 41 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Irbesartan | Irbesartan | 39 | 11 |
| Naproxen | Naproxen | 39 | 11 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | 12 |
| Sertraline Hcl | Sertraline Hcl | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 16 |
| Allopurinol | Allopurinol | 34 | suppressed |
| Clonazepam | Clonazepam | 34 | suppressed |
| Estradiol | Estradiol | 34 | 13 |
| Glipizide | Glipizide | 34 | 11 |
| Prednisone | Prednisone | 33 | 23 |
| Famotidine | Famotidine | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Carvedilol | Carvedilol | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 25 |
| Arnuity Ellipta | Fluticasone Furoate | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Ozempic | Semaglutide | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Furosemide | Furosemide | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Enbrel | Etanercept | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $453.66 · 18 records | SANOFI PASTEUR INC. | ABRYSVO, AIRSUPRA, BEXSERO, BEYFORTUS, BREZTRI, COMIRNATY, ELIQUIS, GEMTESA, GVOKE HYPOPEN, Kerendia, Leqembi, MAVYRET, NURTEC ODT, Ozempic, PEDIARIX, PREVNAR 20, TRELEGY ELLIPTA, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error